EnBiotix Acquires Anti-Microbial Peptide Portfolio from AMP Therapeutics GmbH
PRESS RELEASE | CAMBRIDGE, Mass. and LEIPZIG, Germany (November 3, 2016) – EnBiotix, Inc., a product-focused bioengineering company leveraging systems and synthetic biology platforms to combat the global rise of drug-resistant and drug-tolerant bacterial infections, today announced the completion of an asset acquisition of AMP Therapeutics GmbH (“AMPT”), an anti-microbial peptide portfolio company of Boerhinger Ingelheim Venture Fund and Novartis Venture Fund. In connection with the acquisition, EnBiotix has established EnBiotix GmbH. EnBiotix has also initiated a collaboration with Leipzig University and AMPT’s scientific co-founder, Professor Ralf Hoffmann, Ph.D.
Full Press Release at BusinessWire | November 3rd, 2016